The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Tumor-infiltrating lymphocytes offer potential for novel therapy in panNETs
Mauro Cives, MD, University of Bari Aldo Moro, Bari, Italy, comments on the preclinical findings on tumor-infiltrating lymphocytes (TILs) in pancreatic neuroendocrine tumors (panNETs). Clinically meaningful TILs were obtained in most cases, and TILs with superior metabolic fitness showed anti-tumor activity, which could be enhanced using bispecific T-cell engagers. These data support the potential of TIL-based immunotherapy for panNETs. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Tumor-infiltrating lymphocytes are emerging as an innovative tool for the treatment of cancer. TIL therapy has been already approved in other settings, for example, in patients with melanoma. And we’re currently performing a study trying to demonstrate that the TILs can be also exploited in patients with pancreatic neuroendocrine tumors. We have shown that TILs can be expanded from pancreatic net liver metastases and that they are able to exhibit anti-tumor activity when co-cultivated against the autologous tumoroids...
Tumor-infiltrating lymphocytes are emerging as an innovative tool for the treatment of cancer. TIL therapy has been already approved in other settings, for example, in patients with melanoma. And we’re currently performing a study trying to demonstrate that the TILs can be also exploited in patients with pancreatic neuroendocrine tumors. We have shown that TILs can be expanded from pancreatic net liver metastases and that they are able to exhibit anti-tumor activity when co-cultivated against the autologous tumoroids. In particular, it is quite striking to see that there is great heterogeneity in terms of anti-tumor activity of TILs coming from different tumor regions, that means, in my opinion, that there are immune niches and bystander niches within an individual tumor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
